169 related articles for article (PubMed ID: 6800165)
1. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine].
Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS
Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165
[TBL] [Abstract][Full Text] [Related]
2. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
[TBL] [Abstract][Full Text] [Related]
3. [Isolation and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. An evaluation of the biological properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine].
Ttitova TI; Grigor'ev NI; Antsiferova NG; Radkevich SA; Moroz AF
Zh Mikrobiol Epidemiol Immunobiol; 1985 Jul; (7):14-8. PubMed ID: 3931392
[TBL] [Abstract][Full Text] [Related]
4. [Protective effect of a corpuscular polyvalent Pseudomonas aeruginosa vaccine in generalized chronic Pseudomonas aeruginosa infection in mice with cyclophosphamide-induced leukopenia].
Vetkova LG; Zaĭtsev LG; Khasman EL; Radkevich SA; Moroz AF
Zh Mikrobiol Epidemiol Immunobiol; 1986 Mar; (3):14-8. PubMed ID: 3085409
[TBL] [Abstract][Full Text] [Related]
5. [Derivation and experimental evaluation of polyvalent corpuscular vaccine for prevention of infections caused by Pseudomonas aeruginosa. I. Development of polyvalent corpuscular vaccine].
Moroz AF; Radkevich SA; Antsiferova NG; Brodinova NS
Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):44-9. PubMed ID: 6171956
[No Abstract] [Full Text] [Related]
6. [Cell-free Pseudomonas vaccine: its immunochemical characteristics and immunogenicity].
Bandman OA; Edvabnaia LS; Bulk VF; Zhvanetskaia MI; Mashilova GM
Zh Mikrobiol Epidemiol Immunobiol; 1987 Nov; (11):44-7. PubMed ID: 3124416
[TBL] [Abstract][Full Text] [Related]
7. [Experimentally determined safety and immunological activity of vaccine based on antigens isolated from Pseudomonas aeruginosa in medium K-4].
Nuriddinova NR; Sheremet'ev NN; Ivanova LE; Garib FIu; Iskhakova KhI
Zh Mikrobiol Epidemiol Immunobiol; 2005; (3):57-60. PubMed ID: 16028515
[TBL] [Abstract][Full Text] [Related]
8. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
Zaidi TS; Priebe GP; Pier GB
Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
[TBL] [Abstract][Full Text] [Related]
9. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
[No Abstract] [Full Text] [Related]
10. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
Jones RJ; Roe EA
Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
[TBL] [Abstract][Full Text] [Related]
11. [An experimental study of the immunogenicity of Pseudomonas aeruginosa vaccines].
Akatova NS
Zh Mikrobiol Epidemiol Immunobiol; 1976 May; (5):108-13. PubMed ID: 821271
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the immunological activity of a vaccine from mutant Salmonella minnesota R 595 on a model of experimental Pseudomonas aeruginosa infection in mice].
Likhoded VG; Apollonin AV; Gremiakova TA; Artemova EK
Zh Mikrobiol Epidemiol Immunobiol; 1983 Apr; (4):103-6. PubMed ID: 6408854
[TBL] [Abstract][Full Text] [Related]
13. The epidemiology of Pseudomonas aeruginosa and the development of a polyvalent vaccine.
Pranter W; Staerk J; Zellner R; Zwisler O
Prog Immunobiol Stand; 1971; 5():414-8. PubMed ID: 4633968
[No Abstract] [Full Text] [Related]
14. [Results of a study of the safety, reactogenicity and immunologic effectiveness of pyoimmunogen in the immunization of volunteer donors].
Krokhina MA; Grishina IA; Arkhipova NA; Zarubina EK; Edvabnaia LS
Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):95-8. PubMed ID: 7331614
[TBL] [Abstract][Full Text] [Related]
15. Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine.
Priebe GP; Brinig MM; Hatano K; Grout M; Coleman FT; Pier GB; Goldberg JB
Infect Immun; 2002 Mar; 70(3):1507-17. PubMed ID: 11854239
[TBL] [Abstract][Full Text] [Related]
16. A new polyvalent pseudomonas vaccine.
Merle P; Robbel L; Hungerer KD
Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of a polyvalent corpuscular Pseudomonas aeruginosa vaccine, antibiotics and their combinations in experimental chronic Pseudomonas aeruginosa infection].
Vetkova LG; Antsiferova NG; Radkevich SA; Moroz AF
Zh Mikrobiol Epidemiol Immunobiol; 1985 Mar; (3):51-6. PubMed ID: 3922187
[TBL] [Abstract][Full Text] [Related]
18. [Cell-free Pseudomonas vaccine. IV. Laboratory trials of the effectiveness of experimental Pseudomonas vaccines].
Stanislavskiĭ ES; Joó I; Bulk VF; Zhvanetskaia MI; Mashilova GM
Zh Mikrobiol Epidemiol Immunobiol; 1982 Oct; (10):25-9. PubMed ID: 6817559
[TBL] [Abstract][Full Text] [Related]
19. Study of the immunogenicity of the Pseudomonas aeruginosa polyvalent corpuscular vaccine in human volunteers.
Meitert E; Meitert T; Petrovici M; Sima F; Savulian C; Mitrică N; Georgescu C; Costache G
Arch Roum Pathol Exp Microbiol; 1979; 38(3-4):309-16. PubMed ID: 122593
[No Abstract] [Full Text] [Related]
20. [Principle of constructing polyvalent Pseudomonas aeruginosa vaccines].
Akatova NS
Zh Mikrobiol Epidemiol Immunobiol; 1979 Feb; (2):56-60. PubMed ID: 84457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
